Seelos Therapeutics, Inc. (NASDAQ:SEEL) Short Interest Down 36.9% in June

Seelos Therapeutics, Inc. (NASDAQ:SEEL) was the recipient of a significant drop in short interest in the month of June. As of June 30th, there was short interest totalling 136,100 shares, a drop of 36.9% from the June 15th total of 215,600 shares. Based on an average daily trading volume, of 403,300 shares, the short-interest ratio is presently 0.3 days. Approximately 5.1% of the company’s shares are short sold.

Hedge Funds Weigh In On Seelos Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Modera Wealth Management LLC increased its stake in Seelos Therapeutics by 40.4% during the 3rd quarter. Modera Wealth Management LLC now owns 1,223,776 shares of the company’s stock valued at $225,000 after buying an additional 352,271 shares during the period. Wealth Effects LLC boosted its holdings in shares of Seelos Therapeutics by 104.1% in the first quarter. Wealth Effects LLC now owns 466,660 shares of the company’s stock valued at $276,000 after acquiring an additional 238,067 shares in the last quarter. Finally, Gendell Jeffrey L increased its stake in shares of Seelos Therapeutics by 284.3% during the first quarter. Gendell Jeffrey L now owns 428,966 shares of the company’s stock valued at $254,000 after acquiring an additional 317,351 shares during the period. Institutional investors and hedge funds own 23.37% of the company’s stock.

Seelos Therapeutics Trading Down 11.3 %

Shares of SEEL traded down $0.08 during mid-day trading on Friday, reaching $0.59. 600,732 shares of the stock traded hands, compared to its average volume of 242,826. The stock has a fifty day simple moving average of $1.20 and a 200 day simple moving average of $5.11. Seelos Therapeutics has a 12-month low of $0.47 and a 12-month high of $398.40.

Seelos Therapeutics (NASDAQ:SEEL) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($1.60) earnings per share for the quarter. The business had revenue of $0.58 million during the quarter.

About Seelos Therapeutics

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).